JP2009522292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009522292A5 JP2009522292A5 JP2008548751A JP2008548751A JP2009522292A5 JP 2009522292 A5 JP2009522292 A5 JP 2009522292A5 JP 2008548751 A JP2008548751 A JP 2008548751A JP 2008548751 A JP2008548751 A JP 2008548751A JP 2009522292 A5 JP2009522292 A5 JP 2009522292A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally
- substituted
- halogens
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 95
- 229910052736 halogen Inorganic materials 0.000 claims 61
- 150000002367 halogens Chemical class 0.000 claims 57
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 40
- 125000003342 alkenyl group Chemical group 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000000304 alkynyl group Chemical group 0.000 claims 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 150000001721 carbon Chemical group 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 108010023302 HDL Cholesterol Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims 2
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 claims 2
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 claims 2
- 102000023984 PPAR alpha Human genes 0.000 claims 2
- 230000001548 androgenic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 229960003512 nicotinic acid Drugs 0.000 claims 2
- 235000001968 nicotinic acid Nutrition 0.000 claims 2
- 239000011664 nicotinic acid Substances 0.000 claims 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 102000018616 Apolipoproteins B Human genes 0.000 claims 1
- 108010027006 Apolipoproteins B Proteins 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 108010028554 LDL Cholesterol Proteins 0.000 claims 1
- 229940110346 PPAR gamma partial agonist Drugs 0.000 claims 1
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 claims 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 claims 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 claims 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- -1 and one to four N Chemical group 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229920000080 bile acid sequestrant Polymers 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940125542 dual agonist Drugs 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 229940121380 ileal bile acid transporter inhibitor Drugs 0.000 claims 1
- 229960004738 nicotinyl alcohol Drugs 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 239000002530 phenolic antioxidant Substances 0.000 claims 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims 1
- 229960003912 probucol Drugs 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 0 CC*C(N(CI)*c1ccccc1*)=* Chemical compound CC*C(N(CI)*c1ccccc1*)=* 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75520105P | 2005-12-30 | 2005-12-30 | |
| US60/755,201 | 2005-12-30 | ||
| PCT/US2006/049504 WO2007081570A2 (en) | 2005-12-30 | 2006-12-29 | Cholesteryl ester transfer protein inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009522292A JP2009522292A (ja) | 2009-06-11 |
| JP2009522292A5 true JP2009522292A5 (https=) | 2010-02-12 |
| JP5192392B2 JP5192392B2 (ja) | 2013-05-08 |
Family
ID=38256810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008548751A Expired - Fee Related JP5192392B2 (ja) | 2005-12-30 | 2006-12-29 | コレステリルエステル転送タンパク質阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8865707B2 (https=) |
| EP (1) | EP1973546B1 (https=) |
| JP (1) | JP5192392B2 (https=) |
| AU (1) | AU2006335109B2 (https=) |
| CA (1) | CA2635087A1 (https=) |
| WO (1) | WO2007081570A2 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2678577A1 (en) * | 2007-02-26 | 2008-09-04 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| GB0722769D0 (en) * | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
| EP2137150A1 (en) * | 2007-03-12 | 2009-12-30 | Biolipox AB | Piperidinones useful in the treatment of inflammation |
| JP5470557B2 (ja) * | 2007-07-26 | 2014-04-16 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成 |
| CN101412711A (zh) * | 2007-10-15 | 2009-04-22 | 上海恒瑞医药有限公司 | 氨基甲酸酯类衍生物及其在医药上的应用 |
| AR069207A1 (es) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
| TW200927115A (en) | 2007-11-16 | 2009-07-01 | Boehringer Ingelheim Int | Aryl-and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use |
| US8440658B2 (en) | 2007-12-11 | 2013-05-14 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
| WO2009094169A1 (en) * | 2008-01-24 | 2009-07-30 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| CA2714532A1 (en) * | 2008-02-11 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| WO2009102893A2 (en) | 2008-02-14 | 2009-08-20 | Amira Pharmaceuticals, Inc. | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors |
| US8598160B2 (en) * | 2008-02-15 | 2013-12-03 | Vitae Pharmaceuticals, Inc. | Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| JP2011513242A (ja) | 2008-02-25 | 2011-04-28 | アミラ ファーマシューティカルズ，インク． | プロスタグランジンｄ２受容体アンタゴニスト |
| WO2009117109A1 (en) * | 2008-03-18 | 2009-09-24 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| US8426449B2 (en) | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
| EP2291370B1 (en) | 2008-05-01 | 2013-11-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US8242111B2 (en) * | 2008-05-01 | 2012-08-14 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| JP5696037B2 (ja) * | 2008-05-01 | 2015-04-08 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター |
| RU2531272C2 (ru) | 2008-05-01 | 2014-10-20 | Вайтаи Фармасьютиклз, Инк. | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 |
| AR071719A1 (es) | 2008-05-13 | 2010-07-07 | Boehringer Ingelheim Int | Derivados aliciclicos de acido carboxilico de benzomorfanos y estructuras relacionadas, medicamentos que contienen dichos compuestos y su uso.procesos de obtencion |
| WO2010010157A2 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 |
| NZ590495A (en) | 2008-07-25 | 2012-10-26 | Vitae Pharmaceuticals Inc | Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2323994A1 (en) | 2008-07-25 | 2011-05-25 | Boehringer Ingelheim International GmbH | Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
| JP5679997B2 (ja) * | 2009-02-04 | 2015-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤 |
| TW201039034A (en) * | 2009-04-27 | 2010-11-01 | Chunghwa Picture Tubes Ltd | Pixel structure and the method of forming the same |
| GEP20156309B (en) * | 2009-04-30 | 2015-07-10 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US8680093B2 (en) | 2009-04-30 | 2014-03-25 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US8927539B2 (en) | 2009-06-11 | 2015-01-06 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure |
| WO2010148179A1 (en) * | 2009-06-18 | 2010-12-23 | Japan Tobacco Inc. | Method of treating a disorder associated with mtp |
| EP2448928B1 (en) | 2009-07-01 | 2014-08-13 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| WO2011056737A1 (en) | 2009-11-05 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Novel chiral phosphorus ligands |
| AR078887A1 (es) | 2009-11-06 | 2011-12-07 | Boehringer Ingelheim Int | Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen. |
| WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
| EP2576570A1 (en) | 2010-05-26 | 2013-04-10 | Boehringer Ingelheim International GmbH | 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives |
| WO2011159760A1 (en) | 2010-06-16 | 2011-12-22 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| WO2011161128A1 (en) | 2010-06-25 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
| WO2012059416A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
| TWI537258B (zh) | 2010-11-05 | 2016-06-11 | 百靈佳殷格翰國際股份有限公司 | 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物 |
| HRP20170422T1 (hr) * | 2011-04-12 | 2017-06-16 | Chong Kun Dang Pharmaceutical Corp. | 3-(2-aril-cikloalkenilmetil)-oksazolidin-2-on derivati kao inhibitori transportnog proteina estera kolesterola (cetp) |
| CN102372605B (zh) * | 2011-08-02 | 2014-03-05 | 浙江永太科技股份有限公司 | 一种2-卤代-5-三氟甲基苄醇化合物的制备方法 |
| CN103570499B (zh) * | 2011-08-02 | 2016-04-13 | 浙江永太科技股份有限公司 | 一种2-卤代-5-三氟甲基苄醇化合物的制备方法 |
| WO2013025664A1 (en) | 2011-08-17 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Indenopyridine derivatives |
| EP2934518B1 (en) | 2012-12-19 | 2020-02-19 | Merck Sharp & Dohme Corp. | Spirocyclic cetp inhibitors |
| WO2014099834A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Therapeutic thiazolidinone compounds |
| WO2015017302A2 (en) | 2013-07-30 | 2015-02-05 | Merck Sharp & Dohme Corp. | Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors |
| WO2015054088A1 (en) | 2013-10-10 | 2015-04-16 | Merck Sharp & Dohme Corp. | 3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein |
| CN105814064A (zh) | 2013-12-17 | 2016-07-27 | 默沙东公司 | 作为胆固醇酯转运蛋白的抑制剂的稠合双环异噁唑啉类 |
| EP3174537B1 (en) | 2014-07-29 | 2021-06-23 | Merck Sharp & Dohme Corp. | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
| KR102697816B1 (ko) | 2015-08-05 | 2024-08-21 | 브리스톨-마이어스 스큅 컴퍼니 | 신규 치환된 글리신 유도된 fxia 억제제 |
| CN106117255A (zh) * | 2016-06-20 | 2016-11-16 | 许昌豪丰化学科技有限公司 | 一种苯硼酸的反应液的制取工艺 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776959A (en) * | 1995-06-05 | 1998-07-07 | Washington University | Anticonvulsant and anxiolytic lactam and thiolactam derivatives |
| DE69730980T2 (de) * | 1996-07-31 | 2006-02-23 | Nikken Chemicals Co., Ltd. | 6-phenyltetrahydro-1,3-oxazin-2-on derivate und medizinische zusammensetzungen, die sie enthalten |
| DE19741400A1 (de) * | 1997-09-19 | 1999-03-25 | Bayer Ag | Benzyl-biphenyle |
| KR20020002367A (ko) * | 1998-12-23 | 2002-01-09 | 윌리암스 로저 에이 | 심혈관 징후를 위한 조합물 |
| WO2001054694A1 (en) * | 2000-01-28 | 2001-08-02 | Bristol-Myers Squibb Company | Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
| JP2002187880A (ja) * | 2000-09-27 | 2002-07-05 | Toray Ind Inc | 含窒素化合物及びそれを有効成分とするｃｃｒ３阻害薬 |
| DOP2005000123A (es) * | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
-
2006
- 2006-12-29 WO PCT/US2006/049504 patent/WO2007081570A2/en not_active Ceased
- 2006-12-29 CA CA002635087A patent/CA2635087A1/en not_active Abandoned
- 2006-12-29 US US12/087,189 patent/US8865707B2/en active Active
- 2006-12-29 JP JP2008548751A patent/JP5192392B2/ja not_active Expired - Fee Related
- 2006-12-29 EP EP06849198A patent/EP1973546B1/en not_active Not-in-force
- 2006-12-29 AU AU2006335109A patent/AU2006335109B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009522292A5 (https=) | ||
| JP2009537524A5 (https=) | ||
| JP2006500384A5 (https=) | ||
| JP2004536115A5 (https=) | ||
| JP2008505120A5 (https=) | ||
| RU2345077C2 (ru) | ПРОИЗВОДНЫЕ ПИРИДИНО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ ИНГИБИТОРОВ KDR И FGFR | |
| RU2005138134A (ru) | Получение и применение арилалкильных производных кислот для лечения ожирения | |
| HRP20161631T1 (hr) | Dihidropirazolni gpr40 modulatori | |
| KR940005566A (ko) | 퀴놀린 화합물 | |
| JP5270545B2 (ja) | フラッシングのないナイアシン類似体およびそれらの使用法 | |
| JP2010529203A5 (https=) | ||
| RU2005113713A (ru) | Замещенные (тиазол-2-ил)амиды или сульфонамиды в качестве активаторов глюкокиназы, которые могут применяться при лечении диабета типа 2 | |
| NZ601794A (en) | Di - substituted pyridine derivatives as anticancers | |
| CA2440037A1 (en) | Benzimidazole derivatives for modulating the rage receptor | |
| JP2004506718A5 (https=) | ||
| EA200000155A2 (ru) | 4-фенилпиридиновые производные | |
| JP2006522813A5 (https=) | ||
| JP2005502600A5 (https=) | ||
| RU2007148994A (ru) | Композиции и способы лечения заболевания сетчатки | |
| JP2010508358A5 (https=) | ||
| RU2009136263A (ru) | Производные бензимидазола и способы их применения | |
| RU2009132092A (ru) | Конденсированные ароматические дифторметанфосфонаты в качестве ингибиторов протеинтирозинфосфатазы ib (ptp -1b) | |
| JP2010516700A5 (https=) | ||
| JP2010508359A5 (https=) | ||
| CA2232191A1 (en) | Inhibition of tumor necrosis factor alpha |